Assessment of disease activity and its sequelae in children and adults with myositis

Current Opinion in Rheumatology

Volumn 8, Issue 6, 1996, Pages 495-506

  Rider, Lisa G ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE;

DERMATOMYOSITIS; DIAGNOSTIC APPROACH ROUTE; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; MUSCLE BIOPSY; MUSCLE STRENGTH; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMYOSITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADULT; CHILD; HUMANS; MYOSITIS;

EID: 0030482920     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199611000-00002     Document Type: Review

References (97)

1. Symmons DPM: Disease assessment indices: activity, damage, and severity. Baillieres Clin Rheumatol 1995, 9:267-285. Excellent review defining the concepts of disease activity, damage, and severity and providing principles for validating measures common to all rheumatic diseases.
2. Fries JF, Hochberg MC, Medsger TA Jr, Hunder GG, Bombardier C: Criteria for rheumatic disease: different types and different functions: the American College of Rheumatology Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1994, 37:454-462.
3. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V: American College of Rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727-735. Rigorous validation of a core set of outcome measures for adult rheumatoid arthritis to measure disease activity, which will have utility in therapeutic trials.
4. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, et al: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996, 39:363-369. First validated, comprehensive index in the rheumatic diseases to assess disease damage from prior active inflammation and drug toxicity. Concepts of disease damage, including the rate of progression of irreversible changes, are outlined.
5. White B, Bauer EA, Goldsmith LA, Hochberg MC, Katz LM, Korn JH, Lachenbruch PA, Leroy EC, Mitrane MP, Paulus HE, et al: Guidelines for clinical trials in systemic sclerosis (scleroderma). Arthritis Rheum 1995, 38:351-360. Provides principles for conducting clinical trials in scleroderma, including the development of a disease activity index through the use of nominal group technique.
6. Mader R, Keystone EC: Inflammatory myopathy: do we have adequate measures of the treatment response? J Rheumatol 1993, 20:1105-1107.
7. Fafalak RG, Peterson MG, Kagen LJ: Strength in polymyositis and dermatomyositis: best outcome in patients treated early. J Rheumatol 1994, 21:643-648.
8. Watkins MP, Harris BA: Evaluation of skeletal muscle performance. In Muscle Strength. Edited by Harms-Ringdahl K. Edinburgh: Churchill Livingstone; 1993:19-36.
9. Oddis CV, Medsger TA Jr: Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. J Rheumatol 1988, 15:807-811.
10. Huppertz HI, Kaiser WA: Serial magnetic resonance imaging in juvenile dermatomyositis: delayed normalization. Rheumatol Int 1994, 14:127-129.
11. Resnick JS, Mammel M, Mundale MO, Kottke FJ: Muscle strength as an index of response to therapy in childhood dermatomyositis. Arch Phys Med Rehabil 1981, 62:12-19.
12. Hinderer KA, Hinderer SR: Muscle strength development and assessment in children and adolescents. In Muscle Strength. Edited by Harms-Ringdahl K. Edinburgh: Churchill Livingstone; 1993:93-140.
13. Kendall FP, McCreary EK, Provance PG: Muscles: Testing and Function, edn 4. Baltimore: Williams and Wilkins; 1993.
14. Stoll T, Bruhlmann P, Stucki G, Seifert B, Michel BA: Muscle strength assessment in polymyositis and dermatomyositis: evaluation of the reliability and clinical use of a new, quantitative, easily applicable method. J Rheumatol 1995, 22:473-477. Use of a hand-held pull gauge as a quantitative isometric muscle strength testing technique. Inter- and intrarater reliability was examined for several proximal muscle groups.
15. Kroll MA, Otis JC, Kagen LJ: Abnormalities in quadriceps-hamstring strength: relationships in polymyositis and dermatomyositis. J Rheumatol 1988, 15:1782-1788.
16. Miller LC, Michael AF, Baxter TL, Kim Y: Quantitative muscle testing in childhood dermatomyositis. Arch Phys Med Rehabil 1988, 69:610-613.
17. Dasque F, Laroche M, Marque P, Le Vourc'h P, Moulinier L, Mazieres B, Roques CF: Isokinetic strength testing for evaluating the efficacy of intravenous immune globulin therapy for inclusion body myositis. Rev Rhum Engl Ed 1995, 62:598-601.
18. Convery FR, Minteer MA, Amiel D, Connett KL: Polyarticular disability: a functional assessment. Arch Phys Med Rehabil 1977, 58:494-499.
19. Hicks JE, Thornton B, Richardson D: Comparison of manual muscle test and functional assessment to timed functional tests in patients with polymyositis. Arthritis Rheum 1992, 35(suppl):R9.
20. Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV: A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995, 38:1218-1224. Serial use of the HAQ in polymyositis and dermatomyositis patients with long-standing disease, as an assessment of long-term disability. HAQ-measured disability correlates with disease duration and steroid side effects, such as avascular necrosis.
21. Feldman BM, Ayling-Campos A, Luy L, Stevens D, Silverman ED, Laxer RM: Measuring disability in juvenile dermatomyositis: validity of the Childhood Health Assessment Questionnaire. J Rheumatol 1995, 22:326-331. Validation of the CHAQ as a functional assessment tool in juvenile dermatomyositis, by examination of the relationship of CHAQ scores with muscle strength, sphygmomanometry, and response to clinical change.
22. Lovell DJ, Giannini EH, Rider L, Hicks J, Smith M, Rennebohm R, Lindsley C, for the Juvenile Myositis Collaborative Study Group: Validation and rater reliability of the Childhood Myositis Assessment Scale. Arthritis Rheum 1996, 38(suppl):S183. Validation of an observational functional assessment tool for children assessing muscle strength, function, and endurance. A valuable adjunct for assessing disease activity, particularly in children younger than 5 years of age who cannot undergo MMT.
23. Lane RJ, Emslie-Smith A, Mosquera IE, Hudgson P: Clinical, biochemical and histological responses to treatment in polymyositis: a prospective study. J R Soc Med 1989, 82:333-338.
24. Csuka M, McCarty DJ: Simple method for measurement of lower extremity muscle strength. Am J Med 1985, 78:77-81.
25. Hicks JE, Siegel KL, Miller FW, Rider LG: Muscle strength in key lower extremity muscles predicts walking speed in Juvenile idiopathic inflammatory myopathies. Arthritis Rheum 1996, 39(suppl):S192.
26. Hebert CA, Byrnes TJ, Baethge BA, Wolf RE, Kinasewitz GT: Exercise limitation in patients with polymyositis. Chest 1990, 98:352-357.
27. 31P magnetic resonance spectroscopy in assessing bioenergetics in IIM patients. This technique, including the use of adjunctive isotonic exercise, appears to be very sensitive in detecting low-grade disease activity, including the observation of metabolite changes in dermatomyositis patients without clinical muscle weakness.
28. Newman ED, Kurland RJ: P-31 magnetic resonance spectroscopy in polymyositis and dermatomyositis: altered energy utilization during exercise. Arthritis Rheum 1992, 35:199-203.
29. Kroll M, Otis J, Kagen L: Serum enzyme, myoglobin and muscle strength relationships in polymyositis and dermatomyositis. J Rheumatol 1986, 13:349-355.
30. Hinderks GJ, Frohlich J: Low serum creatine kinase values associated with administration of steroids. Clin Chem 1979, 25:2050-2051.
31. Kagen LJ, Aram S: Creatine kinase activity inhibitor in sera from patients with muscle disease. Arthritis Rheum 1987, 30:213-217.
32. Sanmarti R, Collado A, Gratacos J, Bedini JL, Panella D, Filella X, Llena J, Munoz-Gomez J: Reduced activity of serum creatine kinase in rheumatoid arthritis: a phenomenon linked to the inflammatory response. Br J Rheumatol 1994, 33:231-234.
33. Bohlmeyer TJ, Wu AH, Perryman MB: Evaluation of laboratory tests as a guide to diagnosis and therapy of myositis. Rheum Dis Clin North Am 1994, 20:845-856.
34. Guzman J, Petty RE, Malleson PN: Monitoring disease activity in juvenile dermatomyositis: the role of von Willebrand factor and muscle enzymes. J Rheumatol 1994, 21:739-743.
35. Fraser DD, Frank JA, Dalakas M, Miller FW, Hicks JE, Plotz P: Magnetic resonance imaging in the idiopathic inflammatory myopathies. J Rheumatol 1991, 18:1693-1700.
36. Adams EM, Chow CK, Premkumar A, Plotz PH: The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics 1995, 15:563-574. Excellent, well-illustrated review of the spectrum of MRI abnormalities in adult IIM patients, including correlation with muscle histopathology.
37. Hernandez RJ, Sullivan DB, Chenevert TL, Keim DR: MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol 1993, 161:359-366.
38. Stonecipher MR, Jorizzo JL, Monu J, Walker F, Sutej PG: Dermatomyositis with normal muscle enzyme concentrations: a single-blind study of the diagnostic value of magnetic resonance imaging and ultrasound. Arch Dermatol 1994, 130:1294-1299.
39. Pachman LM, Crawford S, Morrello F, Maduzia L, Caliendoo J, Sufit R, Hellero S: MRI directed muscle biopsy for assessment of juvenile dermatomyositis response to therapy: comparison of initial and follow-up biopsies using a histological rating. Arthritis Rheum 1996, 39(suppl):R14. Inflammation detected on muscle biopsy in the presence of normal MRI findings in juvenile dermatomyositis patients suggests that MRI is less sensitive than biopsy in detecting active myositis.
40. Phoenix J, Betal D, Roberts N, Helliwell TR, Edwards RH: Objective quantification of muscle and fat in human dystrophic muscle by magnetic resonance image analysis. Muscle Nerve 1996, 19:302-310. One of the first studies objectively quantitating MRI signal intensities by measuring pixel densities using mathematical equations.
41. Barkhaus PE, Nandedkar SD, Sanders DB: Quantitative EMG in inflammatory myopathy. Muscle Nerve 1990, 13:247-253.
42. Johnsen B, Fuglsang-Frederiksen A, Vingtoft S, Fawcett P, Liguori R, Nix W, Otte G, Schofield I, Veloso M, Vila A: Inter- and intraobserver variation in the interpretation of electromyographic tests. Electromyogr Clin Neurophysiol 1995, 97:432-443. European multicenter study showing poor reliability of electromyographic readings even in experimental laboratories.
43. Szmidt-Salkowska E, Rowinska-Marcinska K, Lovelace RE: EMG dynamics in polymyositis and dermatomyositis in adults. Electromyogr Clin Neurophysiol 1989, 29:399-404.
44. Fawcett PRW, Barwick DD: The clinical physiology of neuromuscular disease. In Disorders of Voluntary Muscle. Edited by Walton J, Karpati G, Hilton-Jones D. Edinburgh: Churchill Livingstone; 1994:1033-1104.
45. Plotz PH, Dalakas M, Leff RL, Love LA, Miller FW, Cronin ME: Current concepts in the idiopathic inflammatory myopathies: polymyositis, dermatomyositis and related disorders. Ann Intern Med 1989, 111:143-157.
46. Taylor AJ, Wortham DC, Burge JR, Rogan KM: The heart in polymyositis: a prospective evaluation of 26 patients. Clin Cardiol 1993, 16:802-808.
47. Pachman LM: Inflammatory myopathy in children. Rheum Dis Clin North Am 1994, 20:919-942.
48. Vogelgesang SA, Gutierrez J, Klipple GL, Katona IM: Polyneuropathy in juvenile dermatomyositis. J Rheumatol 1995, 22:1369-1372.
49. Jimenez C, Rowe PC, Keene D: Cardiac and central nervous system vasculitis in a child with dermatomyositis. J Child Neurol 1994, 9:297-300.
50. Rider LG, Feldman BM, Rennebohm RM, Lindsley CB, Reed AM, Zemel LS, Ballinger SH, Bowyer SL, Perez ME, Lovell DJ, et al: Physician global assessments of disease activity and disease chronicity in juvenile dermatomyositis: validation and contributing factors. Arthritis Rheum 1996, 39(suppl):R22.
51. Guyatt GH, Townsend M, Berman LB, Keller JL: A comparison of Likert and visual analogue scales for measuring change in function. J Chronic Dis 1987, 40:1129-1133.
52. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT: Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983, 103:882-888.
53. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991, 70:360-374.
54. Commens C, O'Neill P, Walker G: Dermatomyositis associated with multifocal lipoatrophy. J Am Acad Dermatol 1990, 22:966-969.
55. Black CM: Measurement of skin involvement in scleroderma. J Rheumatol 1995, 22:1217-1219. Summarizes the status of the skin thickness score in progressive systemic sclerosis, including several recent validation studies that examine reliability and revise the instrument.
56. Rider LG, Lachenbruch P, Rennebohm R, Wallace C, Zemel L, Lindsley C, Feldman B, Bowyer S, Perez M, Reed A, et al: Identifying skin lesions in dermatomyositis: inter-rater reliability of a new cutaneous assessment tool. Arthritis Rheum 1996, 38(suppl):S168.
57. Pachman LM, Sundberg J, Maduzia L, Daugherty C, Litt D: Sequential studies of nailfold capillary vessels in 10 children with juvenile dermatomyositis: correlation with disease activity score but not von Willebrand factor antigen. Arthritis Rheum 1996, 38(suppl):S360.
58. Crowson AN, Magro CM: The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum Pathol 1996, 27:15-19. Documents membrane-attack complex deposition and endothelial changes in cutaneous capillary vessels in dermatomyositis.
59. Mascaro JM Jr, Hausmann G, Herrero C, Grau JM, Cid MC, Palou J, Mascaro JM: Membrane attack complex deposits in cutaneous lesions of dermatomyositis. Arch Dermatol 1995, 131:1386-1392. Demonstrates complement deposition, including the membrane-attack complex, in dermal capillaries, paralleling similar changes observed in simultaneous muscle biopsy specimens.
60. Schwarz MI: Pulmonary and cardiac manifestations of polymyositis-dermatomyositis. J Thorac Imaging 1992, 7:46-54.
61. Larca LJ, Coppola JT, Honig S: Creatine kinase MB Isoenzyme in dermatomyositis: a noncardiac source. Ann Intern Med 1981, 94:341-343.
62. El Allaf M, Chapelle JP, El Allaf D, Adam A, Faymonville ME, Laurent P, Heusghem C: Differentiating muscle damage from myocardial injury by means of the serum creatine kinase isoenzyme MB mass measurement/total CK activity ratio. Clin Chem 1986, 32:291-295.
63. Bodor GS, Porterfield D, Voss EM, Smith S, Apple FS: Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. Clin Chem 1995, 41:1710-1715.
64. Adams JE, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS: Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation 1993, 88:101-106.
65. Targoff IN: Inflammatory muscle disease. In The Lung in Rheumatic Diseases. Edited by Cannon GW, Zimmerman GA. New York: Marcel Dekker; 1990:303-328.
66. Schwarz MI, Sutarik JM, Nick JA, Leff JA, Emlen JW, Tuder RM: Pulmonary capillaritis and diffuse alveolar hemorrhage: a primary manifestation of polymyositis. Am J Respir Crit Care Med 1995, 151:2037-2040.
67. Clawson K, Oddis CV: Adult respiratory distress syndrome in polymyositis patients with the anti-Jo-1 antibody. Arthritis Rheum 1995, 38:1519-1523.
68. Cronin ME, Miller FW, Plotz PH: A comparison of the approaches for measuring pulmonary disease in patients with idiopathic inflammatory myopathy. Arthritis Rheum 1988, 31(suppl):S122.
69. Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV: Interstitial lung disease in potymyositis and dermatomyositis: clinical features and prognosis as correlated with histologic findings. Am Rev Respir Dis 1990, 141:727-733.
70. Willig TN, Paulus J, Lacau Saint Guily J, Beon C, Navarro J: Swallowing problems in neuromuscular disorders. Arch Phys Med Rehabil 1994, 75:1175-1181.
71. Horowitz M, McNeil JD, Maddern GJ, Collins PJ, Shearman DJ: Abnormalities of gastric and esophageal emptying in polymyositis and dermatomyositis. Gastroenterology 1986, 90:434-439.
72. Sonies BC: Instrumental procedures for dysphagia diagnosis. Semin Speech Lang 1991, 12:185-198.
73. Botet JF, Lightdale C: Endoscopic ultrasonography of the upper gastrointestinal tract. Radiol Clin North Am 1992, 30:1067-1083.
74. Wakamatsu M, Inada K, Tsutsumi Y: Mixed connective tissue disease complicated by pneumatosis cystoides intestinalis and malabsorption syndrome: case report and literature review. Pathol Int 1995, 45:875-878.
75. Lin WY, Wang SJ, Hwang DW, Lan JL, Yeh SH: Technetium-99m-pyrophosphate scintigraphic findings of intestinal perforation in dermatomyositis. J Nucl Med 1995, 36:1615-1617.
76. Tokano Y, Obara T, Hashimoto H, Okumura K, Hirose S: Soluble CD4, CD8 in patients with polymyositis/dermatomyositis. Clin Rheumatol 1993, 12:368-374.
77. Wolf RE, Baethge BA: Interleukin-1 alpha, interleukln-2, and soluble interleukin-2 receptors in polymyositis. Arthritis Rheum 1990, 33:1007-1014.
78. Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, Vischer T, Dayer JM: Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: a biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994, 37:1744-1751.
79. O'Gorman MR, Corrochano V, Roleck J, Donovan M, Pachman LM: Flow cytometric analyses of the lymphocyte subsets in peripheral blood of children with untreated active juvenile dermatomyositis. Clin Diagn Lab Immunol 1995, 2:205-208. Increased B lymphocytes and T helper to T suppressor cell ratios observed in children with early, active juvenile dermatomyositis compared with healthy controls.
80. Miller FW, Love LA, Barbieri SA, Balow JE, Plotz PH: Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol 1990, 81:373-379.
81. De Benedetti F, De Amici M, Aramini L, Ruperto N, Martini A: Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child 1993, 69:232-235.
82. Bloom BJ, Tucker LB, Miller LC, Schaller JG: von Willebrand factor in juvenile dermatomyositis. J Rheumatol 1995, 22:320-325. Serial evaluation of von Willebrand factor antigen in a clinic population of juvenile dermatomyositis patients. Although elevated levels correlate with disease exacerbation, rises in factor VIII-related antigen also occur with intercurrent viral illnesses.
83. Pachman LM, Rother E, Peter HH: Imperfect indications of disease activity in juvenile dermatomyositis. J Rheumatol 1995, 22:193-197. Review of current limitations in assessing disease activity in juvenile dermatomyositis, including excellent analysis of the utility of factor VIII-related antigen and data regarding videomicroscopy of capillary nailfolds.
84. Braun NM, Arora NS, Rochester DF: Respiratory muscle and pulmonary function in polymyositis and other proximal myopathies. Thorax 1983, 38:616-623.
85. Oddis CV, Medsger TA: Relationship between serum creatine phosphokinase level and corticosteroid therapy in polymyositis-dermatomyositis. Arthritis Rheum 1986, 29:S38.
86. Palmieri GMA, Sebes JI, Aelion JA, Moinuddin M, Ray MW, Wood GC, Leventhal MR: Treatment of calcinosis with diltiazem. Arthritis Rheum 1995, 38:1646-1654. Uncontrolled study using diltiazem to treat dystrophic calcification in scleroderma patients; of interest for the radiographic assessments used to monitor responses to therapy, including scintigraphy, MRI, and plain radiographs.
87. Reimers CD, Fleckenstein JL, Witt TN, Muller-Felber W, Pongratz DE: Muscular ultrasound in idiopathic inflammatory myopathies of adults. J Neurol Sci 1993, 116:82-92.
88. Karpati G, Carpenter S: Pathology of the inflammatory myopathies. Baillieres Clin Neurol 1993, 2:527-556.
89. De Jonge FAA, Pauweis EKJ, Hamdy NAT: Scintigraphy in the clinical evaluation of disorders of mineral and skeletal metabolism in renal failure. Eur J Nucl Med 1991, 18:839-855.
90. Fishel B, Diamant S, Papo I, Yaron M: CT assessment of calcinosis in a patient with dermatomyositis. Clin Rheumatol 1986, 5:242-244.
91. Bergler-Klein J, Sochor H, Stanek G, Globits S, Ullrich R, Glogar D: Indium 111-monoclonal antimyosin antibody and magnetic resonance imaging in the diagnosis of acute Lyme myopericarditis. Arch Intern Med 1993, 153:2696-2700.
92. Buchpiguel CA, Roizenblatt S, Lucena-Fernandes MF, Soares Junior J, Meneguetti JC, Hironaka FH, Cossermelli W, Camargo EE: Radioisotopic assessment of peripheral and cardiac muscle involvement and dysfunction in polymyositis/dermatomyositis. J Rheumatol 1991, 18:1359-1363.
93. Hill C, Romas E, Kirkham B: Use of sequential DTPA clearance and high resolution computerized tomography in monitoring interstitial lung disease in dermatomyositis. Br J Rheumatol 1996, 35:164-166. A novel approach for assessing ILD associated with myositis, for which few reliable methods currently exist.
94. Wells AU, Hansell DM, Rubens MB, Cullinan P, Black CM, Dubois RM: The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Rev Respir Dis 1993, 148:1076-1082.
95. Ramsay SC, Yeates MG, Burke WMJ, Bryant DH, Morgan GW, Breit SN: Quantitative pulmonary gallium scanning in interstitial lung disease. Eur J Nucl Med 1992, 19:80-85.
96. Wells AU, Hansell DM, Harrison NK: Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J 1993, 6:797-802.
97. Schumacher HR, Schimmer B, Gordon GV, Bookspan MA, Brogadir S, Dorwart BB: Articular manifestations of polymyositis and dermatomyositis. Am J Med 1979, 67:287-292.